Remarkably, 17 major gene changes identified in the Cyp1b1-ko liver have been associated with the reversal of conditions associated with metabolic syndrome or Type 2 diabetes, when introduced as single genetic modifications (Table 4). Eighty percent of these changes are conserved in the older female mice, which retain the suppression of liver steatosis and adiposity with Cyp1b1 deletion. Cyp1b1 metabolites may, therefore, modulate processes that are central to the adverse effects of NASH and Type 2 diabetes.
